Related content

The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia

By Schaefer Hans   Lübbert Michael  

Annals of Hematology, Vol. 84, Iss. 13, 2005-12 ,pp. : 67-79

Springer Publishing Company

Access to resources Recommend Favorite

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

By Wijermans P.   Lübbert M.   Verhoef G.   Klimek V.   Bosly A.  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 9-17

Springer Publishing Company

Access to resources Recommend Favorite

In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies

By Hackanson Björn   Robbel Christian   Wijermans Pierre   Lübbert Michael  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 32-38

Springer Publishing Company

Access to resources Recommend Favorite

Myelodysplasia

By Schiller Gary J.   Reese Nicholas  

Hematology, Vol. 18, Iss. 5, 2013-09 ,pp. : 307-308

Maney Publishing

Access to resources Recommend Favorite

2-Morpholinoethylisocyanide as a coupling agent for hapten-protein conjugates

By Brandon David   Binder Ronald  

Food and Agricultural Immunology, Vol. 17, Iss. 1, 2006-03 ,pp. : 53-61

Taylor & Francis Ltd

Access to resources Recommend Favorite